

Author Index Volume 18 (2017)

The issue number is given in front of the pagination

- Abbaszadegan, M.R., see Sheibani, S. (4) 349–356
Abern, M.R., see Fantony, J.J. (4) 381–387
Abramov, M., see Heydarov, R. (3) 265–272
Akyol, M., A. Alacacioglu, L. Demir, Y. Kucukzeybek, Y. Yildiz, Z. Gumus, M. Kara, T. Salman, U. Varol, H. Taskaynatan, U. Oflazoglu, V. Bayoglu and M.O. Tarhan, The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy (4) 441–449
Alacacioglu, A., see Akyol, M. (4) 441–449
Al-Malki, A.L., see Zohny, S.F. (4) 413–423
Aristizabal-Pachon, A.F. and W.O. Castillo, Role of GSK3 β in breast cancer susceptibility (2) 169–175
Asadi, M.H., see Soheili, S. (1) 69–77
Azhati, B., see Tusong, H. (1) 79–85
- Bahari, G., see Hashemi, M. (2) 155–159
Baothman, O.A., see Zohny, S.F. (4) 413–423
Bayoglu, V., see Akyol, M. (4) 441–449
Bizhani, F., see Hashemi, M. (2) 155–159
Bogina, G., see Caliò, A. (2) 215–220
Borkowska, E., see Pietrusiński, M. (1) 47–59
Borowiec, M., see Pietrusiński, M. (1) 47–59
Botros, S.K.A., see Zayed, R.A. (2) 177–182
Bozkurt, E., see Yazici, P. (1) 19–25
Bria, E., see Caliò, A. (2) 215–220
Brunelli, M., see Caliò, A. (2) 215–220
- Caliò, A., E. Bria, S. Pilotto, E. Gilioli, A. Nottesgar, A. Eccher, L. Cima, A. Santo, S. Pedron, G. Turri, S. Knuutila, M. Chilosi, F. Vanzo, G. Bogina, A. Terzi, G. Tortora, A. Scarpa, M. Loda, G. Martignoni and M. Brunelli, *ALK* gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes (2) 215–220
Cao, L., see Wu, Z. (1) 35–39
- Carvalho, I.N.S.R., A.H.O. Reis, A.C.E. dos Santos and F.R. Vargas, A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma (3) 313–317
Castillo, W.O., see Aristizabal-Pachon, A.F. (2) 169–175
Chamani, J., see Sheibani, S. (4) 349–356
Charoensuk, L., see Rucksaken, R. (1) 27–34
Chen, D., see Pan, Y. (4) 357–366
Chen, F., X.-F. Li, D.-S. Fu, J.-G. Huang and S.-E. Yang, Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma (2) 209–214
Chen, H., see Luo, D. (3) 273–284
Chen, J., see Huang, K. (3) 231–239
Chen, Q.-Y., see Li, G.-J. (3) 241–248
Chen, W.-M., see Lin, Y. (4) 339–347
Chen, X.-Y., see Lin, Y. (4) 339–347
Chen, Y.-M., see Yuan, L.-Q. (4) 329–338
Chen, Z., see Luo, D. (3) 273–284
Cherdyntsev, E., see Cherdyntseva, N. (3) 291–296
Cherdyntseva, N., P. Gervas, E. Voropaeva, E. Denisov, L. Pisareva, E. Malinovskaya, V. Maksimov, M. Voevoda, D. Perinov, Y. Panferova, E. Cherdyntsev and E. Choynzonov, New variants in the *BRCA1* gene in Buryat Mongol breast cancer patients: Report from two families (3) 291–296
Chevolot, Y., see Shi, L. (2) 105–116
Chilosi, M., see Caliò, A. (2) 215–220
Choudhry, H., see Zohny, S.F. (4) 413–423
Choynzonov, E., see Cherdyntseva, N. (3) 291–296
Chu, H., see Lu, M. (2) 143–148
Cima, L., see Caliò, A. (2) 215–220
Cong, H., see Lu, M. (2) 143–148
Cong, H., see Shen, X. (3) 257–263
Constantinou, M., see Pietrusiński, M. (1) 47–59
- Danesh, H., see Hashemi, M. (2) 155–159
Daoud, J., see Debouki-Joudi, S. (2) 133–141

- Dar, M., see Malik, S.A. (4) 389–395
- Debouki-Joudi, S., F. Trifa, A. Khabir, T. Sellami-Boudawara, M. Frikha, J. Daoud and R. Mokdad-Gargouri, CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients (2) 133–141
- Demir, L., see Akyol, M. (4) 441–449
- Demir, U., see Yazici, P. (1) 19–25
- Deng, Z.-Q., see Zhai, L.-L. (3) 305–312
- Denisov, E., see Cherdyntseva, N. (3) 291–296
- Ding, G., see Wu, Z. (1) 35–39
- Donaires, F.S., P.R.D.V. Godoy, G.S. Leandro, D. Puthier and E.T. Sakamoto-Hojo, E2F transcription factors associated with up-regulated genes in glioblastoma (2) 199–208
- dos Santos, A.C.E., see Carvalho, I.N.S.R. (3) 313–317
- Dou, L., see Pan, Y. (4) 357–366
- Du, W., T. Shen, H. Li, Y. Liu, L. He, L. Tan and M. Hu, Urinary NGAL for the diagnosis of the renal injury from multiple myeloma (1) 41–46
- Eccher, A., see Caliò, A. (2) 215–220
- El-Shinawi, M., see Zohny, S.F. (4) 413–423
- Eltaweel, M.A., see Zayed, R.A. (2) 177–182
- Eroglu, C., see Kurtul, N. (4) 459–466
- Faghih, Z., see Shahriari, S. (4) 375–380
- Fang, Z.-L., see Li, G.-J. (3) 241–248
- Fantony, J.J., T.A. Longo, A. Gopalakrishna, R. Owusu, R.S. Lance, W.-C. Foo, B.A. Inman and M.R. Abern, Urinary NID2 and twist1 methylation to augment conventional urine cytology for the detection of bladder cancer (4) 381–387
- Farsinejad, A., see Soheili, S. (1) 69–77
- Foo, W.-C., see Fantony, J.J. (4) 381–387
- Frikha, M., see Debouki-Joudi, S. (2) 133–141
- Fu, D.-S., see Chen, F. (2) 209–214
- Fu, Z., see Hu, J. (1) 87–94
- Fu, Z., see Yu, Y. (3) 319–327
- Gao, F., see Li, J. (1) 11–17
- Gao, X., see Guo, Y. (1) 1–9
- Ge, X., see Li, J. (1) 11–17
- Gervas, P., see Cherdyntseva, N. (3) 291–296
- Gholamin, M., see Sheibani, S. (4) 349–356
- Gilioli, E., see Caliò, A. (2) 215–220
- Godoy, P.R.D.V., see Donaires, F.S. (2) 199–208
- Goodarzi, M.T., see Rahimi, F. (1) 61–68
- Gopalakrishna, A., see Fantony, J.J. (4) 381–387
- Guan, J., see Tusong, H. (1) 79–85
- Gumus, Z., see Akyol, M. (4) 441–449
- Guo, J., see Sun, W. (4) 397–403
- Guo, W., see Huang, X.-H. (2) 183–190
- Guo, Y., see Shen, X. (3) 257–263
- Guo, Y., Y. Pang, X. Gao, M. Zhao, X. Zhang, H. Zhang, B. Xuan and Y. Wang, MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1 (1) 1–9
- Han, J., Q. Meng, Q. Xi, H. Wang and G. Wu, PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells (3) 249–256
- Hao, Y.-K., see Zhang, X.-H. (4) 405–411
- Harrison, T.J., see Li, G.-J. (3) 241–248
- Hashemi, M., H. Danesh, F. Bizhani, B. Narouie, M. Sotoudeh, A. Nouralizadeh, F. Sharifiaghdas, G. Bahari and M. Taheri, Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer (2) 155–159
- He, L., see Du, W. (1) 41–46
- Heydarov, R., S. Titov, M. Abramov, E. Timofeev and V. Mikhailovich, Hydrogel microarray for detection of polymorphisms in the *UGT1A1*, *DPYD*, *GSTP1* and *ABCB1* genes (3) 265–272
- Hong, X., see Yang, Z.-Y. (1) 95–104
- Hong, Z., H. Li, L. Li, W. Wang and T. Xu, Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer (2) 125–131
- Hu, H., see Shan, X.H. (4) 367–374
- Hu, J., C. Li, C. Liu, S. Zhao, Y. Wang and Z. Fu, Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC (1) 87–94
- Hu, L.-P., see Li, G.-J. (3) 241–248
- Hu, M., see Du, W. (1) 41–46
- Huang, B., X. Liu, C. Sun, L. Wang and L. Yang, Association of single nucleotide polymorphisms in the coding region of *Bcl-2* with the occurrence and prognosis of colorectal cancer: A case-control study (4) 433–439
- Huang, J.-G., see Chen, F. (2) 209–214
- Huang, K., J. Chen, M.-S. Yang, Y.-J. Tang and F. Pan, Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells (3) 231–239
- Huang, K., see Luo, D. (3) 273–284
- Huang, M., see Luo, D. (3) 273–284
- Huang, X.-H., R.-H. Liang, L. Su, W. Guo and C.-J. Wang, Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment (2) 183–190

- Huang, Z., see Zhang, L. (3) 221–230
- Inman, B.A., see Fantony, J.J. (4) 381–387
- Isil, G.R., see Yazici, P. (1) 19–25
- İzmirli, M., see Kurtul, N. (4) 459–466
- Jędrzejczyk, A., see Pietrusiński, M. (1) 47–59
- Jia, J., see Song, L. (4) 425–432
- Jiang, C., see Yan, X. (2) 191–198
- Jing, R., see Lu, M. (2) 143–148
- Jing, W., see Luo, P. (3) 285–290
- Ju, S., see Lu, M. (2) 143–148
- Ju, S., see Shen, X. (3) 257–263
- Kałużewski, B., see Pietrusiński, M. (1) 47–59
- Kang, D., see Yan, X. (2) 191–198
- Kara, M., see Akyol, M. (4) 441–449
- Karimi, J., see Rahimi, F. (1) 61–68
- Kępczyński, Ł., see Pietrusiński, M. (1) 47–59
- Khabir, A., see Debouki-Joudi, S. (2) 133–141
- Khan, M.S., see Malik, S.A. (4) 389–395
- Khodadadi, I., see Rahimi, F. (1) 61–68
- Khorramzadeh, M.R., see Shahriari, S. (4) 375–380
- Khuntikeo, M., see Rucksaken, R. (1) 27–34
- Knuutila, S., see Caliò, A. (2) 215–220
- Kucukzeybek, Y., see Akyol, M. (4) 441–449
- Kurtul, N., E.A. Taşdemir, D. Ünal, M. İzmirli and C. Eroglu, SPARC: As a prognostic biomarker in rectal cancer patients treated with chemoradiotherapy (4) 459–466
- Lan, Q., see Yuan, L.-Q. (4) 329–338
- Lance, R.S., see Fantony, J.J. (4) 381–387
- Laurencea, E., see Shi, L. (2) 105–116
- Leandro, G.S., see (2) 199–208
- Li, B., see Ma, K. (3) 297–303
- Li, C., see Hu, J. (1) 87–94
- Li, G.-J., Q.-Y. Chen, T.J. Harrison, X.-Y. Wang, L.-P. Hu, Q.-L. Yang, K.-W. Li and Z.-L. Fang, Des- γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T¹⁷⁶², A¹⁷⁶⁴), a prospective study (3) 241–248
- Li, H., see Du, W. (1) 41–46
- Li, H., see Hong, Z. (2) 125–131
- Li, H., see Luo, D. (3) 273–284
- Li, J., M. Li, F. Gao and X. Ge, Serum microRNA-15a level acts as a potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma (1) 11–17
- Li, J.-Q., X. Yang and X.-M. Zhou, *PIM1* gene silencing inhibits proliferation and promotes apoptosis of human esophageal cancer cell line Eca-109 (2) 149–154
- Li, K.-W., see Li, G.-J. (3) 241–248
- Li, L., see Hong, Z. (2) 125–131
- Li, M., see Li, J. (1) 11–17
- Li, N.-D., see Luo, P. (3) 285–290
- Li, P., see Yu, Y. (3) 319–327
- Li, T., see Sun, W. (4) 397–403
- Li, W., see Ma, K. (3) 297–303
- Li, X., see Luo, D. (3) 273–284
- Li, X.-F., see Chen, F. (2) 209–214
- Li, Y., see Song, L. (4) 425–432
- Liang, C., see Yu, Y. (3) 319–327
- Liang, C.-Z., see Luo, P. (3) 285–290
- Liang, R.-H., see Huang, X.-H. (2) 183–190
- Lin, J., see Zhai, L.-L. (3) 305–312
- Lin, S., see Luo, D. (3) 273–284
- Lin, Y., see Yan, X. (2) 191–198
- Lin, Y., W.-M. Chen, C. Wang and X.-Y. Chen, MicroRNA profiling in peripheral T-cell lymphoma, not otherwise specified (4) 339–347
- Liu, B., see Yang, Z.-Y. (1) 95–104
- Liu, C., see Hu, J. (1) 87–94
- Liu, D., see Qi, M. (4) 451–458
- Liu, P., see Pan, Y. (4) 357–366
- Liu, P., see Zhang, L. (3) 221–230
- Liu, X., see Huang, B. (4) 433–439
- Liu, Y., see Du, W. (1) 41–46
- Loda, M., see Caliò, A. (2) 215–220
- Long, M., see Luo, D. (3) 273–284
- Longo, T.A., see Fantony, J.J. (4) 381–387
- Lu, H.-Y., see Shan, X.H. (4) 367–374
- Lu, M., S. Ju, X. Shen, X. Wang, R. Jing, C. Yang, H. Chu and H. Cong, Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer (2) 143–148
- Lu, P., see Luo, D. (3) 273–284
- Luo, D., H. Chen, P. Lu, X. Li, M. Long, X. Peng, M. Huang, K. Huang, S. Lin, L. Tan, Y. Zhu, Z. Chen, N. Ouyang and H. Li, CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma (3) 273–284
- Luo, P., W. Jing, M. Zhu, N.-D. Li, H. Zhou, M.-X. Yu, C.-Z. Liang and J.-C. Tu, Decreased expression of LncRNA SRA1 in hepatocellular carcinoma and its clinical significance (3) 285–290

- Ma, K., W. Xu, C. Wang, B. Li, K. Su and W. Li, Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy (3) 297–303
- Mahmoudian, R.A., see Sheibani, S. (4) 349–356
- Maksimov, V., see Cherdyntseva, N. (3) 291–296
- Malik, S.A., M.S. Khan, M. Dar, M. Ul Hussain and S. Mudassar, TAZ is an independent prognostic factor in non-small cell lung carcinoma: Elucidation at protein level (4) 389–395
- Malinovskaya, E., see Cherdyntseva, N. (3) 291–296
- Maolakuerban, N., see Tusong, H. (1) 79–85
- Martignoni, G., see Caliò, A. (2) 215–220
- Memar, B., see Sheibani, S. (4) 349–356
- Meng, Q., see Han, J. (3) 249–256
- Mihmanli, M., see Yazici, P. (1) 19–25
- Mikhailovich, V., see Heydarov, R. (3) 265–272
- Mo, X., see Sun, W. (4) 397–403
- Moghimi, H.R., see Shahriari, S. (4) 375–380
- Mokdad-Gargouri, R., see Debouki-Joudi, S. (2) 133–141
- Mudassar, S., see Malik, S.A. (4) 389–395
- Nankali, M., see Rahimi, F. (1) 61–68
- Narouie, B., see Hashemi, M. (2) 155–159
- Nottegar, A., see Caliò, A. (2) 215–220
- Nouralizadeh, A., see Hashemi, M. (2) 155–159
- Nuerrula, Y., see Tusong, H. (1) 79–85
- Oflazoglu, U., see Akyol, M. (4) 441–449
- Ouyang, N., see Luo, D. (3) 273–284
- Owusu, R., see Fantony, J.J. (4) 381–387
- Pairojkul, C., see Rucksaken, R. (1) 27–34
- Pan, F., see Huang, K. (3) 231–239
- Pan, J., see Yan, X. (2) 191–198
- Pan, Y., P. Liu, D. Chen and L. Dou, Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin (4) 357–366
- Panferova, Y., see Cherdyntseva, N. (3) 291–296
- Pang, Y., see Guo, Y. (1) 1–9
- Pedron, S., see Caliò, A. (2) 215–220
- Peng, W., see Zhai, L.-L. (3) 305–312
- Peng, X., see Luo, D. (3) 273–284
- Perinov, D., see Cherdyntseva, N. (3) 291–296
- Pietrusiński, M., Ł. Kępczyński, A. Jędrzejczyk, E. Borkowska, M. Traczyk-Borszyńska, M. Constantinou, B. Kałużewski and M. Borowiec, Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes (1) 47–59
- Pilotto, S., see Caliò, A. (2) 215–220
- Pinlaor, P., see Rucksaken, R. (1) 27–34
- Pinlaor, S., see Rucksaken, R. (1) 27–34
- Pisareva, L., see Cherdyntseva, N. (3) 291–296
- Puthier, D., see Donaires, F.S. (2) 199–208
- Qi, J., see Shen, X. (3) 257–263
- Qi, M., D. Liu and S. Zhang, MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer (4) 451–458
- Qi, S., see Yan, X. (2) 191–198
- Qi, Y. and W. Wang, Clinical significance of circulating tumor cells in squamous cell lung cancer patients (2) 161–167
- Rahimi, F., J. Karimi, M.T. Goodarzi, M. Saidijam, I. Khodadadi, A.N.E. Razavi and M. Nankali, Overexpression of receptor for advanced glycation end products (RAGE) in ovarian cancer (1) 61–68
- Razavi, A.N.E., see Rahimi, F. (1) 61–68
- Reis, A.H.O., see Carvalho, I.N.S.R. (3) 313–317
- Rexiati, M., see Tusong, H. (1) 79–85
- Rezaeifard, S., see Shahriari, S. (4) 375–380
- Rucksaken, R., L. Charoensuk, P. Pinlaor, C. Pairojkul, N. Khuntikeo and S. Pinlaor, Plasma orosomucoid 2 as a potential risk marker of cholangiocarcinoma (1) 27–34
- Saidijam, M., see Rahimi, F. (1) 61–68
- Sakamoto-Hojo, E.T., see Donaires, F.S. (2) 199–208
- Salman, T., see Akyol, M. (4) 441–449
- Santo, A., see Caliò, A. (2) 215–220
- Scarpa, A., see Caliò, A. (2) 215–220
- Sellami-Boudawara, T., see Debouki-Joudi, S. (2) 133–141
- Shahriari, S., S. Rezaeifard, H.R. Moghimi, M.R. Khorramizadeh and Z. Faghieh, Cell membrane and intracellular expression of toll-like receptor 9 (TLR9) in colorectal cancer and breast cancer cell-lines (4) 375–380
- Shan, X.H., P. Wang, F. Xiong, H.-Y. Lu and H. Hu, Detection of human breast cancer cells using a 2-deoxy-D-glucose-functionalized superparamagnetic iron oxide nanoparticles (4) 367–374
- Sharifiaghdas, F., see Hashemi, M. (2) 155–159
- Sheibani, S., R.A. Mahmoudian, M.R. Abbaszadegan, J. Chamani, B. Memar and M. Gholamin, Expression analysis of matrix metalloproteinase-13 in human gastric cancer in the presence of Helicobacter Pylori infection (4) 349–356
- Shen, T., see Du, W. (1) 41–46

- Shen, X., see Lu, M. (2) 143–148
- Shen, X., Y. Zhang, X. Wu, Y. Guo, W. Shi, J. Qi, H. Cong, X. Wang, X. Wu and S. Ju, Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum (3) 257–263
- Shi, L., Y. Chevolut, E. Souteyrand and E. Laurencea, Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer (2) 105–116
- Shi, W., see Shen, X. (3) 257–263
- Soheili, S., M.H. Asadi and A. Farsinejad, Distinctive expression pattern of OCT4 variants in different types of breast cancer (1) 69–77
- Song, L., H. Yu, J. Jia and Y. Li, A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis (4) 425–432
- Sotoudeh, M., see Hashemi, M. (2) 155–159
- Souteyrand, E., see Shi, L. (2) 105–116
- Su, K., see Ma, K. (3) 297–303
- Su, L., see Huang, X.-H. (2) 183–190
- Sun, C., see Huang, B. (4) 433–439
- Sun, C., see Yuan, L.-Q. (4) 329–338
- Sun, D.-S., see Zhang, X.-H. (4) 405–411
- Sun, W., X. Mo, T. Li, Y. Xie and J. Guo, Clinical significance of the long noncoding RNA RP11-19P22.6-001 in gastric cancer (4) 397–403
- Taheri, M., see Hashemi, M. (2) 155–159
- Tan, G.-Q., see Zhang, X.-H. (4) 405–411
- Tan, L., see Du, W. (1) 41–46
- Tan, L., see Luo, D. (3) 273–284
- Tan, Q., see Yu, Y. (3) 319–327
- Tang, X., see Zhai, L.-L. (3) 305–312
- Tang, Y.-J., see Huang, K. (3) 231–239
- Tarhan, M.O., see Akyol, M. (4) 441–449
- Taşdemir, E.A., see Kurtul, N. (4) 459–466
- Taskaynatan, H., see Akyol, M. (4) 441–449
- Terzi, A., see Caliò, A. (2) 215–220
- Thin, K.Z., see Yu, Y. (3) 319–327
- Timofeev, E., see Heydarov, R. (3) 265–272
- Titov, S., see Heydarov, R. (3) 265–272
- Tortora, G., see Caliò, A. (2) 215–220
- Traczyk-Borszyńska, M., see Pietrusiński, M. (1) 47–59
- Trifa, F., see Debouki-Joudi, S. (2) 133–141
- Tu, J., see Yu, Y. (3) 319–327
- Tu, J.-C., see Luo, P. (3) 285–290
- Turri, G., see Caliò, A. (2) 215–220
- Tusong, H., N. Maolakuerban, J. Guan, M. Rexiati, W.-G. Wang, B. Azhati, Y. Nuerrula and Y.-J. Wang, Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma (1) 79–85
- Ul Hussain, M., see Malik, S.A. (4) 389–395
- Ünal, D., see Kurtul, N. (4) 459–466
- Vanessa, M.-E.D., see Zhai, L.-L. (3) 305–312
- Vanzo, F., see Caliò, A. (2) 215–220
- Vargas, F.R., see Carvalho, I.N.S.R. (3) 313–317
- Varol, U., see Akyol, M. (4) 441–449
- Voevoda, M., see Cherdyntseva, N. (3) 291–296
- Voropaeva, E., see Cherdyntseva, N. (3) 291–296
- Wang, Y.-J., see Tusong, H. (1) 79–85
- Wang, C., see Lin, Y. (4) 339–347
- Wang, C., see Ma, K. (3) 297–303
- Wang, C.-J., see Huang, X.-H. (2) 183–190
- Wang, D.-L., see Yuan, L.-Q. (4) 329–338
- Wang, H., see Han, J. (3) 249–256
- Wang, L., see Huang, B. (4) 433–439
- Wang, M., see Yang, Z.-Y. (1) 95–104
- Wang, P., see Shan, X.H. (4) 367–374
- Wang, W., see Hong, Z. (2) 125–131
- Wang, W., see Qi, Y. (2) 161–167
- Wang, W.-G., see Tusong, H. (1) 79–85
- Wang, X., see Lu, M. (2) 143–148
- Wang, X., see Shen, X. (3) 257–263
- Wang, X.-Y., see Li, G.-J. (3) 241–248
- Wang, Y., see Guo, Y. (1) 1–9
- Wang, Y., see Hu, J. (1) 87–94
- Wang, Z.-Y., see Yuan, L.-Q. (4) 329–338
- Wu, C. and D. Zhang, Identification of early-stage lung adenocarcinoma prognostic signatures based on statistical modeling (2) 117–123
- Wu, G., see Han, J. (3) 249–256
- Wu, X., see Shen, X. (3) 257–263
- Wu, X., see Shen, X. (3) 257–263
- Wu, Z., L. Zhou, G. Ding and L. Cao, Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma (1) 35–39
- Xi, Q., see Han, J. (3) 249–256
- Xie, W.-P., see Zhang, X.-H. (4) 405–411
- Xie, Y., see Sun, W. (4) 397–403
- Xiong, F., see Shan, X.H. (4) 367–374
- Xu, T., see Hong, Z. (2) 125–131
- Xu, W., see Ma, K. (3) 297–303
- Xuan, B., see Guo, Y. (1) 1–9

- Yan, X., D. Kang, J. Pan, C. Jiang, Y. Lin and S. Qi, Osteoblastic differentiation and cell calcification of adamantinomatous craniopharyngioma induced by bone morphogenetic protein-2 (2) 191–198
- Yang, C., see Lu, M. (2) 143–148
- Yang, F., see Yang, Z.-Y. (1) 95–104
- Yang, L., see Huang, B. (4) 433–439
- Yang, M.-S., see Huang, K. (3) 231–239
- Yang, Q.-L., see Li, G.-J. (3) 241–248
- Yang, S.-E., see Chen, F. (2) 209–214
- Yang, X., see Li, J.-Q. (2) 149–154
- Yang, Z.-Y., F. Yang, Y.-L. Zhang, B. Liu, M. Wang, X. Hong, Y. Yu, Y.-H. Zhou and H. Zeng, LncRNA-ANCR down-regulation suppresses invasion and migration of colorectal cancer cells by regulating EZH2 expression (1) 95–104
- Yazici, P., U. Demir, E. Bozkurt, G.R. Isil and M. Mihmanli, The role of red cell distribution width in the prognosis of patients with gastric cancer (1) 19–25
- Yildiz, Y., see Akyol, M. (4) 441–449
- Yin, J.-Y., see Zhai, L.-L. (3) 305–312
- Yu, H., see Song, L. (4) 425–432
- Yu, M., see Yu, Y. (3) 319–327
- Yu, M.-X., see Luo, P. (3) 285–290
- Yu, Y., J. Zuo, Q. Tan, K.Z. Thin, P. Li, M. Zhu, M. Yu, Z. Fu, C. Liang and J. Tu, Plasma *miR-92a-2* as a biomarker for small cell lung cancer (3) 319–327
- Yu, Y., see Yang, Z.-Y. (1) 95–104
- Yuan, L.-Q., Y.-M. Chen, C. Sun, Z.-Y. Wang, D.-L. Wang and Q. Lan, Actein inhibits glioma growth via a mitochondria-mediated pathway (4) 329–338
- Zaki, M.A., see Zayed, R.A. (2) 177–182
- Zamzami, M.A., see Zohny, S.F. (4) 413–423
- Zayed, R.A., M.A. Eltaweel, S.K.A. Botros and M.A. Zaki, MN1 and PTEN gene expression in acute myeloid leukemia (2) 177–182
- Zeng, H., see Yang, Z.-Y. (1) 95–104
- Zhai, L.-L., J. Zhou, J. Zhang, X. Tang, L.-Y. Zhou, J.-Y. Yin, M.-E.D. Vanessa, W. Peng, J. Lin and Z.-Q. Deng, Down-regulation of pseudogene *Vimentin 2p* is associated with poor outcome in de novo acute myeloid leukemia (3) 305–312
- Zhang, D., see Wu, C. (2) 117–123
- Zhang, H., see Guo, Y. (1) 1–9
- Zhang, H., see Zhang, L. (3) 221–230
- Zhang, J., see Zhai, L.-L. (3) 305–312
- Zhang, L., Z. Huang, H. Zhang, M. Zhu, W. Zhu, X. Zhou and P. Liu, Prognostic value of candidate microRNAs in gastric cancer: A validation study (3) 221–230
- Zhang, S., see Qi, M. (4) 451–458
- Zhang, X., see Guo, Y. (1) 1–9
- Zhang, X.-H., Y. Zhang, W.-P. Xie, D.-S. Sun, Y.-K. Zhang, Y.-K. Hao and G.-Q. Tan, Expression and significance of calreticulin in human osteosarcoma (4) 405–411
- Zhang, Y., see Shen, X. (3) 257–263
- Zhang, Y., see Zhang, X.-H. (4) 405–411
- Zhang, Y.-K., see Zhang, X.-H. (4) 405–411
- Zhang, Y.-L., see Yang, Z.-Y. (1) 95–104
- Zhao, M., see Guo, Y. (1) 1–9
- Zhao, S., see Hu, J. (1) 87–94
- Zhou, H., see Luo, P. (3) 285–290
- Zhou, J., see Zhai, L.-L. (3) 305–312
- Zhou, L., see Wu, Z. (1) 35–39
- Zhou, L.-Y., see Zhai, L.-L. (3) 305–312
- Zhou, X., see Zhang, L. (3) 221–230
- Zhou, X.-M., see Li, J.-Q. (2) 149–154
- Zhou, Y.-H., see Yang, Z.-Y. (1) 95–104
- Zhu, M., see Luo, P. (3) 285–290
- Zhu, M., see Yu, Y. (3) 319–327
- Zhu, M., see Zhang, L. (3) 221–230
- Zhu, W., see Zhang, L. (3) 221–230
- Zhu, Y., see Luo, D. (3) 273–284
- Zohny, S.F., O.A. Baothman, M. El-Shinawi, A.L. Al-Malki, M.A. Zamzami and H. Choudhry, The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer (4) 413–423
- Zuo, J., see Yu, Y. (3) 319–327